© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
September 15, 2021
The latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.
September 12, 2021
The results come from a posthoc analysis of the pivotal phase 3 ARCHES trial.
September 10, 2021
Adding N-803 to Bacille Calmette-Guérin achieved a complete response in nearly three-fourths of patients with BCG-unresponsive, non-muscle invasive bladder cancer.
February 24, 2021
Papillary renal cell carcinoma (RCC) is a rare malignancy, accounting for 15% of all RCC cases.